1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part Three: Final Firms Enjoy Mixed Fortunes

Declines See A Handful Of Players Slide Down The Chart As Others Climb Our Ranking

 
• By Dave Wallace

In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.

Generics Bulletin Top 50 2023
Off-patent firms have seen mixed fortunes in the past year • Source: Shutterstock

After the first part of this year’s Generics Bulletin Top 50 showed two new players entering the top 10 and the second looked at how firms in the middle of our ranking were faring (see sidebar), this third section of our annual feature reflects positive and negative changes among lower-placed firms that have led to some meaningful movements at the bottom of the table in 2023.

Leading off our third table is Endo, which jumps up from position 34 last year to 31st place this year, amid growth for the company in our lead category of Generics/Biosimilars/APIs/OTC sales and as a few firms in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

Generics Bulletin’s Top 50 Ranking For 2024

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: Firms Fall Out Of Final Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.

The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

The Generics Bulletin Top 50, Part One: Top Ten Ranking Conceals Changes For Industry Leaders

 
• By Dave Wallace

A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.

More from Market Intelligence

Vardenafil Leads UK Rises In January

 
• By Dave Wallace

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.

UK Gabapentin Prices Shoot Up In December

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

UK Memantine Prices Spike In November

 
• By Dave Wallace

Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.